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ABSTRACT
Objectives There is a clear need to understand the
factors that might prevent and/or facilitate the effective
use of HIV treatment as prevention (TasP) at an
individual level. This paper reports on ﬁndings from the
ﬁrst qualitative study in the UK exploring the
acceptability of TasP among gay, bisexual and/or men
who have sex with men (MSM) and migrant African
communities in Scotland.
Methods We conducted seven exploratory focus group
discussions (FGDs) with convenience samples of MSM
(ﬁve FGDs, n=22) and mixed-gender African (two FGDs,
n=11) participants. Of these, three FGDs were
conducted with HIV-positive MSM (n=14) and one FGD
with HIV-positive Africans (n=8). We then conducted 34
in-depth interviews (IDIs) with a purposive sample of
MSM (n=20) and Africans (n=14, women=10). Half
were HIV-positive (MSM, n=10; African, n=7). FGD and
IDI data were analysed thematically drawing on
predetermined and emergent themes.
Results We found that inequalities in HIV literacy could
be a barrier to TasP, as could social constraints, such as
criminalisation of transmission, increased risk of sexually
transmitted infection and increased burden of treatment.
We also identiﬁed psychological barriers such as
perceptions of risk. However, relationships and shared
decision making were identiﬁed as potential facilitators
for TasP.
Conclusions Our results suggest that potential use
and management of TasP may not be straightforward.
It could be contingent on reducing inequalities in HIV
literacy, minimising the perceived burden of treatment
and other potential risks, and addressing the dynamics
of existing and socially acceptable risk management
strategies, especially in relation to long-term
serodiscordant relationships.
BACKGROUND
The discovery that antiretrovirals (ARVs) can
prevent onward sexual transmission of HIV has sig-
niﬁcant implications for HIV prevention. Growing
evidence has demonstrated that an HIV-positive
person taking ARVs with undetectable viraemia is
highly unlikely to transmit HIV to an unprotected
sexual partner.1–3 UK HIV-expert organisations
have endorsed this position, stating that the
absence of sexually transmitted infections (STIs)
and regular adherence to ARVs, in addition to
undetectable viraemia, is an effective method of
preventing HIV transmission in vaginal sex and
signiﬁcantly reduces risk in anal sex.4 Evidence also
suggests treatment as prevention (TasP) works at
community level through reducing population-level
viraemia.5–7 WHO guidelines advise treatment ini-
tiation at a CD4 count of 5008 while a number of
cities (San Francisco, Vancouver) and countries
(France) have introduced policies to encourage the
immediate treatment of people diagnosed with
HIV to reduce community viral load and new
infections.9 10 However, evidence from the UK sug-
gests a limited impact on community-level effective-
ness11 and current UK treatment guidelines advise
early treatment decisions be made on an individual
basis.12
The effectiveness of TasP at a population level
relies upon maximising the number of HIV-positive
people at each level of the treatment cascade: (i)
diagnosed with HIV, (ii) currently in care, (iii)
taking ARVs and (iv) suppressed viraemia.13
Although the population-level treatment cascade
has received much attention, there has been limited
consideration at an individual level as to whether
potential recipients of TasP will ﬁnd this prevention
strategy acceptable.14 Our review found only three
such studies. These studies identiﬁed limited aware-
ness of TasP, as well as scepticism about its effect-
iveness to prevent HIV transmission. There is a
clear need to understand the factors that might
prevent and/or facilitate the effective use of TasP.
Drawing on extensive international evidence of
HIV prevention successes and failures, Kippax and
Stephenson have argued that a social public health
approach is needed to better facilitate the use of
ARVs for HIV prevention.15 That is, there is a need
to understand the social context in which
TasP-related HIV prevention is implemented. As we
have argued elsewhere, this means that understand-
ing the acceptability of TasP requires moving
beyond expressions of willingness or adherence to
medication and identifying the broader social, cul-
tural and structural factors that will affect potential
uptake and sustained effectiveness of TasP.14 This
paper reports on ﬁndings from the ﬁrst qualitative
study in the UK exploring the acceptability of TasP
among communities most affected by HIV. We
identify a range of social factors and constraints
that could affect the uptake and use of TasP on an
individual level.
METHODS
We employed mixed qualitative methods to explore
the acceptability of TasP with the two communities
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most affected by HIV in Scotland: (1) gay, bisexual and/or men
who have sex with men (MSM) and (2) men and women from
migrant African communities. While Scotland is a low
HIV-prevalence setting, these two communities represent over
half of all new HIV diagnoses.16 We included HIV-positive and
HIV-negative and/or untested participants in the study given the
relational nature of sex and HIV prevention. First, we con-
ducted seven exploratory focus group discussions (FGDs) with
convenience samples of MSM (ﬁve FGDs, n=22) and mixed-
gender African (two FGDs, n=11) participants aged 18–
75 years recruited through community and/or support groups
with the assistance of sexual health organisations in Glasgow,
Edinburgh, Motherwell and Selkirk between August and
November 2012. Of these, three FGDs were conducted with
HIV-positive MSM (n=14) and one FGD with HIV-positive
Africans (n=8). Participants were ﬁrst asked about their under-
standings and management of sexual health risks, focusing on
the role of sexual health technologies within these strategies. To
facilitate discussion, participants were presented with a range of
items, such as condoms, sachets of lubricant, a home pregnancy
test, an emptied bottle of Truvada (ARV medication), a mock-up
bottle of antibiotics, a list of ARVs available in the European
Union, and images of an Oraquick® In-Home HIV test and a
rapid, ﬁngerprick HIV test. In the second part, pre-exposure
prophylaxis (PrEP) and TasP were explained to participants with
the help of visual aids (ﬁgure 1). Participants were asked to
discuss PrEP and TasP in relation to their own sexual health,
including if and how they might be used, and to identify any
barriers or facilitators to their use. Participants received £15
vouchers and travel costs at the end of FGD.
We then conducted 34 in-depth interviews (IDIs) between
March and September 2013 to explore issues emerging from
FGD ﬁndings and examine personal risk management practices
in further depth. The purposive sample comprised MSM (n=20)
and Africans (n=14, women=10) aged 19–60 years from
Glasgow, Lothian, Lanarkshire and Grampian, half of whom had
been diagnosed with HIV at the time of the interview (MSM,
n=10; African, n=7). Recruitment was conducted via targeted
ﬂyers, posters and emails distributed through clinical, community
and culturally speciﬁc non-sexual health avenues. Participants
received £20 vouchers. Semistructured interviews explored PrEP
and TasP acceptability within the context of existing risk manage-
ment strategies. The ﬁrst part of the interview focused on per-
sonal experiences of and perspectives on HIV, sexual health risk
management practices and use of sexual health technologies.
Participants were presented with a list of sexual health technolo-
gies that included all of the objects used in FGDs. The second
part of the interview focused on the acceptability of PrEP and
TasP, exploring awareness, potential use, concerns and combin-
ation with existing risk management strategies. The focus group
and interview topic guides are available in the online supplemen-
tary material.
All FGDs and IDIs were digitally recorded and transcribed ver-
batim. Transcripts were anonymised and coded in NVivo 10. Data
were analysed thematically, drawing on predetermined and emer-
gent themes.17 18 Rigour throughout the analysis was achieved
through an iterative process of discussion with coauthors and revi-
sion of ﬁndings.17–21 In this paper, we present ﬁndings from the
TasP-related discussions. Illustrative extracts referred to by number
in the following section are provided in box 1.
RESULTS
A range of factors that could affect the acceptability and uptake
of TasP were identiﬁed and are described below.
Awareness and HIV literacy
Lack of awareness and inequalities in HIV literacy were identi-
ﬁed as barriers to TasP. Participants expressed very limited
awareness of TasP as a ‘branded’ HIV prevention strategy.
There appeared to be limited awareness of the link between sup-
pressed viral loads and reduced levels of infectiousness.
Awareness was affected by serostatus, with predominantly
HIV-positive participants reporting knowledge of the link
between an undetectable viral load and reduced HIV transmis-
sion. However, almost all of the participants, regardless of seros-
tatus, appeared to struggle with the idea that someone living
with HIV might not be infectious. For many, this doubt was
grounded in the simple association of infectiousness with an
HIV diagnosis, regardless of treatment status or viral load.
Inequalities in HIV literacy skills among participants also
affected TasP acceptability. For those, mostly HIV-negative parti-
cipants unfamiliar with clinical terminology such as undetect-
able viral loads, TasP could be misunderstood and exacerbate
stigma (1A). However, some of the HIV-positive participants
described scepticism of TasP on the basis of their in-depth HIV
knowledge (1B), highlighting how awareness and knowledge
alone may not translate straightforwardly as acceptability.
Social constraints and other risks
A number of social constraints were identiﬁed as barriers to
TasP. HIV-positive participants, especially African men and
women and MSM who had been living with HIV for a number
of years, were critical of TasP as they expressed concerns about
the burden of treatment, such as the daily work of taking ARVs
(2A). HIV-positive participants also described other risks that
might emerge as a result of TasP and/or that TasP would not
address, such as the criminalisation of HIV transmission, the
risk of STIs and the potential for developing resistance to treat-
ment (2B).
Perceptions of risk and TasP candidacy
Perception of risk was identiﬁed as an important psychological
barrier to TasP candidacy. Our analysis showed clear differences
in the ways that HIV-positive and HIV-negative participants
considered risk in relation to TasP. HIV-negative participants
commonly expressed an unwillingness to consider TasP as a pre-
vention strategy in a serodiscordant sexual relationship due to a
perception of high risk of HIV transmission (3A). Responses of
many of these participants were generally framed by fear of any
sexual contact with a known HIV-positive sexual partner.
For the remaining, largely HIV-positive participants, TasP was
not embraced as a primary prevention strategy because of a low
perception of risk of HIV transmission and a perceived lack of
need for additional protection. Most described practising mul-
tiple methods of HIV prevention, including reliance on
condoms, serosorting, avoiding ‘high-risk’ sexual acts or abstain-
ing entirely from sex. These participants not only described
their existing risk reduction strategies as effective, but also the
extent to which they worked to maintain these efforts. As a
result, most perceived risk of onward HIV transmission as
minimal and were not immediately convinced of the need for
additional protection. Moreover, all HIV-positive participants
not taking ARVs expressed a desire to delay treatment initiation.
One participant rejected TasP when it was offered to him in
clinic because he was conﬁdent that risk of HIV transmission
was minimal with his serodiscordant partners because he was
already using condoms (3B). He further explained how his
rejection of TasP was compounded by the perceived burden of
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treatment (eg, side effects, more easily identiﬁed as
HIV-positive, increased insurance costs, worsened mental
health). It appeared that for these HIV-positive participants, the
added protection that TasP offered was neither necessary (as a
result of existing risk-reduction strategies) nor a sufﬁcient trade-
off for their potential treatment burden. The latter could be
avoided by delaying treatment initiation until deemed clinically
necessary.
Perceptions of treatment
Many HIV-negative participants described the perceived inevit-
ability of taking ARVs and subsequent preventative beneﬁts of
treatment as a positive step for HIV prevention. While the
broader beneﬁts of good health and protecting a sexual partner
contributed to this perspective, some HIV-negative participants
identiﬁed social stigma as a potential barrier to TasP (4A). This
FGD extract illustrates the social tensions between the impera-
tive for people living with HIV to prevent onward transmission
at any cost and the perceived experiences of HIV-related stigma
and treatment burden. Moreover, many HIV-positive
participants, especially African women, described a perception
of constrained choice in relation to treatment initiation and the
broader public health imperative of HIV prevention (4B).
Relationships and shared decision making
The relational context of sex was identiﬁed as a potential facili-
tator to TasP among HIV-positive participants. Reliance on TasP
without condoms was something that many HIV-positive parti-
cipants said they would only consider in long-term serodiscor-
dant relationships and with the ‘right’ partner (5A). While
participants appeared cautious about the sexual partners with
whom they would rely only on TasP, many were also optimistic
about the possibilities TasP enabled, especially in terms of
improved intimacy in long-term relationships. For example, one
HIV-positive participant described how a previous serodiscor-
dant relationship might have worked out differently if he had
known about TasP (5B).
The decision to rely only on TasP within long-term sexual
relationships was not a decision HIV-positive participants felt
they could make alone, and many described how it would be a
Figure 1 Treatment as prevention
(TasP) card.
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Box 1 Findings
1. Awareness and HIV literacy
A. Limited awareness
he said that he had a low viral load and it was undetectable and…I remember googling it ’cause I was like ’what the hell does
he mean?’ and, of course, because he said it was undetectable, I was thinking ’so that means that I could get it but then mine
isn’t detectable?’ So…I was thinking ‘I don’t want…I don’t want to put myself at risk and then I get an undetectable one and
then they can’t tell me I’ve got HIV because it’s undetectable.’ (HIV-negative MSM, IDI)
B. Diverse HIV literacy skills
Well, if they said ‘by taking your anti-viral medication’—and I do take it on time or anything like that, I’m good that way—
[…]‘it makes your blood levels undetectable but it also makes your semen level undetectable.’ Then you’d be thinking
differently. But they don’t. (HIV-positive MSM, IDI)
2. Social constraints and other risks
A. Burden of treatment
R1: The other point like the job of taking medication, [it] is not good…. It’s frustrating ‘cause, it’s not like side effects, it’s just
the idea of the work. I don’t know, wake up in the morning have to take something it’s…you can’t have that freedom…I wake
up, I just ok, you have to always getting them. The [partner] should agree with the condoms all the time…
R2: I just want to say from my experiences what I’ve seen that when people are faced with taking medication, it’s that ‘do I take
the medication now?’ is what we’re saying, it might be taking it every day, every day is frustrating. Or do I wait until I’m ill to
start taking it? (HIV-positive African FGD)
B. Other risks
R1: If you’re having unprotected sex without a condom, you’re leaving yourself open to prosecution.
Q: Even if your viral load is undetectable?
R1: That’s irrelevant.
R2: Aye. You’re still putting the guy at risk.
R1: It’s irrelevant, coz you’re still, even though you’re undetectable, you’ve still got HIV and you possibly could pass it on, so
there’s still […]
Q: So actually, using a condom is about…legally protecting yourself? […]
R1: …no, it’s no just legally, but from what they’ve got as well, coz you don’t know what they’ve got. It’s no just yourself. Well,
it’s no just them you’re protecting, it’s yourself.
R2: Mm hmm, coz you don’t know their sexual health status, you know, if you don’t ask, and then a lot of them will tell you
lies, anyway.
R1: And again, if they’re already on any medication, the fact that you’ve got your viral load to come down to non-detectable,
the last thing you want is to go into something where it goes back up again and you’re having to re-ﬁght the whole battle
again.
R2: Then, the thing is…, what is it, the medicine, like, see the tablets, like if you pick up a different strain.
R3: Yeah, it can become resistant.
R2: It can become resistant to the tablets, as well, so there’s a lot at stake, know what I mean? (HIV-positive MSM FGD)
3. Perception of risk and treatment as prevention (TasP) candidacy
A. High perception of risk, HIV-negative/untested
a bit risky (HIV-negative African woman, IDI)
not safe (HIV-negative African man, IDI)
Like Russian roulette (HIV-negative MSM, IDI)
B. Low perception of risk, HIV-positive
I was getting a sort of spate of sort of infections then they said ‘maybe think about starting you on treatment to prevent other
people from getting it’. I said no, it’s because I was barebacking with sort of other positive guys I’m getting a lot more
infections from them. I’m, whenever I was with negative guys I always used condoms so the risk of me passing it onto an
HIV-negative guy’s like very, very, very low because I use condoms… (HIV-positive MSM, IDI)
4. Perceptions of treatment
A. Social expectations to start treatment
R1: If I was HIV and they gave me those drugs I would take them every day because…eventually you’re gonna be taking drugs
all the way through your life ‘cause you know it’s helping you. So I don’t think it would be a problem for them to be taking a
drug that’s helping them.
R2: Some people know, they might get fed up of taking the drugs and hiding as well as you said there, they hide yeah? They
can’t go to anywhere they like without packing their drugs, they would be carrying their bag as if is baby, they can’t leave their
bag no, at some point and they don’t see any changes. They might stop. Some people might get depressed and stop…
R1: …if people have a motivation, a reason for continuing to take the ARVs whether it’s for good health, whether it’s for
keeping their partner safe. I think they are more likely to keep taking the ARVs… (HIV-negative African FGD)
B. Constrained choices
don’t really have a choice because when we’re pregnant we have to be on medication whether you like it or not.
(HIV-positive African FGD)
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shared decision with a serodiscordant partner (5C). However,
inequalities within relationships, especially in relation to gender
and serostatus, were described by participants as complicating
this shared decision making (5D). This was not a topic partici-
pants took lightly, and some described the difﬁculties in
knowing if, how and when to raise the issue with a partner who
may have limited HIV literacy (5E). Although shared decision
making in sexual relationships was identiﬁed as a potential facili-
tator to TasP, many HIV-positive participants described feeling
in a vulnerable position within serodiscordant sexual relation-
ships. This meant potentially deferring TasP-related decisions to
their sexual partners, if they were able to raise it at all.
DISCUSSION
This is the ﬁrst study of TasP acceptability among communities
affected by HIV in the UK. We found limited awareness of TasP,
as noted elsewhere.22 23 We identiﬁed a number of barriers and
facilitators to uptake, and our results suggest that potential use
and management of TasP may not be straightforward. It could
be contingent on reducing inequalities in HIV literacy, minimis-
ing the perceived burden of treatment and other potential risks,
and addressing the dynamics of existing and socially acceptable
risk management strategies, especially in relation to long-term
serodiscordant relationships.
Our ﬁndings in relation to TasP awareness and limited engage-
ment with the contemporary science of HIV risk demonstrate
that inequalities in HIV literacy could be a major barrier to TasP.
While some HIV-positive participants demonstrated knowledge
of clinical indicators of HIV risk, most participants expressed
little understanding of and trust in the effect of non-detectable
viraemia on risk of HIV transmission. This had implications not
only for TasP but for identiﬁcation of risk in relation to HIV
more generally. Our ﬁndings echo Holt et al,24 who reported
that Australian HIV-negative MSM were more sceptical than
HIV-positive MSM of reduced risk of transmission with
undetectable viral loads. Our ﬁndings suggest the need to
address diverse levels of HIV literacy, especially in relation to
the effective identiﬁcation of and response to HIV risk based on
contemporary clinical understandings of HIV, to ensure the
appropriate understanding and uptake of TasP.
Our study identiﬁed a number of constraints to the effective
and ethical use of TasP, especially in relation to additional risks
for people living with HIV, such as risk of criminalisation of
transmission or increased risk of STIs. While Kalichman et al
reported an association between the belief that undetectable
viral loads reduced HIV infectiousness and contracting a new
STI in a US study with HIV-positive individuals,25 participants
in our research were anxious about such risks. Moreover, parti-
cipants expressed concerns about the burden of treatment that
TasP might augment, for instance, through the additional work
of adherence,26 poor mental health and the perceived con-
strained treatment choices resulting from the public health
imperative to prevent HIV transmission. These ﬁndings demon-
strate how TasP could increase the burden of prevention experi-
enced by people diagnosed with HIV through the increased
social, psychological and physical work in managing risk with
ARVs. Although current HIV treatment guidelines in the UK
state that the decision to start treatment must not be due to
pressure from others,12 supporting people diagnosed with HIV
in relation to TasP needs to consider the potential impact of
these social burdens.
Interestingly, HIV-positive participants would only consider
TasP and non-condom use with long-term serodiscordant part-
ners. We suggest that potential non-condom use within this spe-
ciﬁc context should not be viewed as risk compensation,28 but
as a carefully thought out risk reduction strategy within a
trusted, monogamous relationship. In this way, relationships and
shared decision making were identiﬁed as potential facilitators
for TasP. Although participants did not always feel in a position
to negotiate non-condom use, TasP did enable some to imagine
improved longer-term sexual relationships. Consequently, TasP
was seen in some cases as a prevention method with the poten-
tial for improved sexual health and well-being. These ﬁndings
highlight the need to support shared decision making within
relationships, while addressing potential inequalities, to achieve
shared risk reduction through TasP.
Limitations
With a small sample of MSM and migrant African participants
from a low HIV prevalence setting, some of whom were
engaged in sexual health or community services, our ﬁndings
are not generalisable to a wider population but are transferable
to similar populations in similar social contexts. For many in
this study, TasP was a hypothetical concept and ﬁndings will be
limited as a result of few direct experiences with TasP. However,
our use of focus groups minimises this potential limitation as it
addresses the social context and anticipated uptake of
products.27
5. Relationships and shared decision making
A. Initiating TasP as a prevention strategy with the right partner
I don’t think I would start using it just for, like, anybody, I think, but if it was sort of a, someone, a very long term thing and,
you know, we’d discussed everything. (HIV-positive MSM, IDI)
B. Supporting the sustainability of relationship
So perhaps if he’d known, or we’d known about, been told about those things, then it might have made it sort of, in your head
sort of made you think, ‘right, this could go, you know, I would get what I want out of this long, relationship long-term.’
(HIV-positive MSM, IDI)
C. Joint decision making
If you discuss it with your partner, and then if she says, ‘it’s ok we can…we can not use condoms.’ Then that’s ﬁne. Yeah,
that’s ﬁne, as long as you agree on what to do, the two of you. (HIV-positive African man, IDI)
D. Inequalities within relationships
It’s up to him as well isn’t it? To be convinced to say ‘yeah, it’s safe now.’ (HIV-positive African woman, IDI)
this guy I’m seeing now, you know, I’d like to have bareback sex wi’ him. But thinking how do I bring that issue up with him?
And how would he…what would he think of me then? Would he be thinking ’are you fucking…you’re willing to put my life at
risk,’ you know? Because he wouldn’t know anything about…I feel, I sometimes feel like saying to him ‘I’ve printed all this off
for you, go and read it.’ But that’s forcing somebody into something that if…if he felt like that…I think he knows that I would
like to do that because of certain signs or something I’ve given him, but we’ve never discussed it. (HIV-positive MSM, IDI)
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CONCLUSION
The acceptability of TasP at an individual level will affect how
effective it is as a population-level HIV prevention intervention.
Our ﬁndings demonstrate that there is a need to improve HIV
literacy and increase knowledge about TasP among those most
affected by HIV so that informed and equitable treatment and
risk reduction choices can be made. The recent Community
Consensus Statement on TasP called for the safeguarding of the
health and well-being of people living with HIV within the
context of TasP,28 and our study highlights how effective imple-
mentation and support of TasP also needs to pay attention to
the social and sexual context within which TasP will be used.
Without this, we would suggest it has little chance of affecting
on HIV prevention at the community level.
Key messages
▸ There is a clear need to understand the factors that might
prevent and/or facilitate the effective use of treatment as
prevention (TasP) at an individual level.
▸ Inequalities in HIV literacy, social constraints such as
treatment burden and perceptions of risk were identiﬁed as
potential barriers to TasP.
▸ Relationships and shared decision making were identiﬁed as
potential facilitators to the effective use of TasP.
▸ TasP will be contingent on addressing inequalities in HIV
literacy and other social constraints, and engaging with the
dynamics of existing and socially acceptable risk
management strategies.
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